Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASCO 2023 | Phase I study of ruxolitinib plus abemaciclib for patients with myelofibrosis

Prithviraj Bose • 4 Jun 2023

ASCO 2023

Myelofibrosis Myeloproliferative Neoplasms Abemaciclib Ruxolitinib

Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, sheds light on a Phase I trial (NCT05714072) evaluating the safety of ruxolitinib in combination with the CDK4/6 inhibitor abemaciclib in patients with myelofibrosis (MF) for patients with a suboptimal response to ruxolitinib monotherapy. Preclinical studies have shown synergistic activity between abemaciclib and ruxolitinib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Current and emerging treatments for MF: an update from ASH 2023

Prithviraj Bose • 11 Dec 2023

An update from LIMBER-104: zilurgisertib +/- ruxolitinib in the management of MF-associated anemia

Prithviraj Bose • 11 Dec 2023

Bezuclastinib in adult patients with non-advanced systemic mastocytosis: initial results from Summit

Prithviraj Bose • 11 Dec 2023

LIMBER-104: zilurgisertib +/- ruxolitinib in patients with MF-associated anemia

Prithviraj Bose • 6 Sep 2023

Related Videos

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

JAK inhibitor combination therapy for the treatment of myelofibrosis

Ruben Mesa • 9 Dec 2023

XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF

John Mascarenhas • 10 Dec 2023

Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis

John Mascarenhas • 10 Dec 2023